# ANTICIPATED ACQUISITION BY ROCHE DIAGNOSTICS LIMITED OF CERTAIN ASSETS HELD BY LUMIRADX GROUP LIMITED (IN ADMINISTRATION) AND LUMIRADX INTERNATIONAL LIMITED (IN ADMINISTRATION)

23 May 2024

NOTICE UNDER SECTION 96(2A) OF THE ENTERPRISE ACT 2002PUBLISHED PURSUANT TO SECTION 107(1)(I) OF THE ENTERPRISE ACT 2002

The Competition and Markets Authority ( CMA ) hereby gives notice pursuant to section 96(2A) of the Enterprise Act 2002 (the Act ) that the merger notice provided by (i) Roche Diagnostics Limited ( Roche ) and (ii) LumiraDx Group Limited (in administration) and LumiraDx International Limited (in administration) ( LumiraDx ) in relation to Rocheâ€™s acquisition of certain assets of LumiraDx (the Transaction ) meets the requirements of section 96(2) of the Act.

The initial period defined in section 34ZA(3) of the Act in relation to the Transaction will therefore commence on the first working day after the date of this notice, ie on 24 May 2024. The deadline for the CMA to announce its decision whether to refer the Merger for a phase 2 investigation is therefore 19 July 2024.